[Form 4] MIRA PHARMACEUTICALS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Denil Shekhat, a director of MIRA PHARMACEUTICALS, INC. (MIRA), reported on Form 4 that on 10/01/2025 she acquired 22,378 restricted shares of the issuer's common stock at a price of $1.35 per share. The filing shows the shares were issued as compensation in connection with the issuer's acquisition of SKNY Pharmaceuticals, Inc. Following the transaction the reporting person beneficially owns 22,378 shares in a direct ownership form. The Form 4 was signed on 10/03/2025 and was filed by one reporting person.

Insights

Insider Transactions Analyst

Director received 22,378 restricted shares at $1.35 tied to an acquisition.

The Form 4 discloses a single non-derivative issuance of 22,378 restricted common shares on 10/01/2025 to Denil Shekhat. The filing explicitly states these shares were issued as compensation related to the issuer's acquisition of SKNY Pharmaceuticals, Inc.

This is a compensation issuance, not an open-market trade, and the shares are reported as direct beneficial ownership following the transaction. The filing does not provide vesting terms, resale restrictions, or the impact on total outstanding shares.

Corporate Governance Expert

Disclosure shows director compensation tied to an acquisition; governance impact is procedural disclosure.

The report identifies the reporting person as a director and shows the Form 4 was filed by one reporting person and signed on 10/03/2025. The document ties insider compensation to an acquisition transaction, which is a governance disclosure of related-party economic effects.

The filing contains no additional governance details such as board approvals, conflict statements, or terms of the acquisition; those items are not disclosed in this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shekhat Denil Nanji

(Last) (First) (Middle)

C/O MIRA PHARMACEUTICALS, INC.

1200 BRICKELL AVE. SUITE 1950 #1183

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MIRA PHARMACEUTICALS, INC. [ MIRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	10/01/2025	10/01/2025	A		22,378	A	$1.35(1)	22,378	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 22,378 restricted shares of common stock, par value $0.0001 of the Issuer issued as compensation for the Issuer's acquisition of SKNY Pharmaceuticals, Inc.

	/s/ Denil Shekhat	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MIRA director Denil Shekhat report on Form 4 (MIRA)?

The Form 4 reports acquisition of 22,378 restricted shares on 10/01/2025 at a price of $1.35 per share.

Why were the 22,378 shares issued to the director?

The filing states the shares were issued as compensation in connection with MIRA's acquisition of SKNY Pharmaceuticals, Inc..

What is the ownership form reported after the transaction?

The shares are reported as direct ownership, with 22,378 shares beneficially owned following the transaction.

When was the Form 4 signed and filed?

The signature on the Form 4 is dated 10/03/2025 and the reported transaction date is 10/01/2025.

Does the Form 4 disclose vesting or resale restrictions for these shares?

No; the Form 4 states the shares are restricted but does not disclose specific vesting terms or resale restrictions.